Fifth US Biosimilar To Herceptin Launched By Merck

Ontruzant Biosimilar Available For All Eligible Indications

 
• By Dean Rudge
  
Crowds
The biosimilar trastuzumab market in the US is becoming increasingly crowded, with five players • Source: Shutterstock

More from Biosimilars

More from Products